GlassScriptPhysician profile
Gilda Gomez
NPI 1235321753
$1,247.38
in general payments reported to CMS, 2019-2025
25 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2021: $34.18 · 2022: $75.32 · 2023: $313 · 2024: $211 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439 · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.24 |
| Education | $252.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $194.43 | 2019-2023 | Padcev |
| Janssen Biotech, INC. | $132.28 | 2019-2023 | Erleada |
| Novartis Pharmaceuticals Corporation | $101.09 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $94.04 | 2019-2025 | Tagrisso, Imfinzi, Enhertu |
| Celgene Corporation | $85.74 | 2019-2025 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $83.19 | 2024-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $73.04 | 2019-2024 | Keytruda |
| Daiichi Sankyo INC. | $54.48 | 2022-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $50.87 | 2019-2025 | Opdivo |
| Genzyme Corporation | $45.44 | 2019-2022 | |
| Pfizer INC. | $42.78 | 2019-2024 | |
| Genentech USA, INC. | $32.85 | 2019 | |
| Amgen INC. | $31.48 | 2019 | |
| Abbvie INC. | $28.40 | 2019-2024 | |
| Lilly USA, LLC | $28.25 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $27.40 | 2022 | |
| Servier Pharmaceuticals LLC | $22.01 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.28 | 2019 | |
| Eisai INC. | $17.81 | 2024 | |
| Gilead Sciences, INC. | $17.12 | 2021 | |
| Sobi, INC | $14.92 | 2024 | |
| Spectrum Pharmaceuticals INC. | $13.46 | 2023 | Rolvedon |
| Puma Biotechnology, INC. | $13.38 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.78 | 2019 | |
| Heron Therapeutics, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilda Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.